The CVC sepsis rate of 2.32 per patient-year was obtained from the US Renal Data System.¹ The CVC sepsis hospitalization cost was calculated as $27,088 from the Healthcare Cost and Utilization Project 2010 Nationwide Inpatient Sample and converted to 2014 dollars using the Medical Consumer Price Index. 3, 7 -Hospitalization costs were estimated using a combination of ICD-9-CM diagnosis codes to determine the costs for hospitalization of specific ESRD CVC patients with sepsis.
-Hospital admissions with a primary diagnosis code of 999.31-infection due to CVC with secondary diagnosis codes, 585.6-ESRD, and 995.91-sepsis and / or 995.92-severe sepsis, were used to determine the appropriate patient population. 
Design
Non-randomized, multi-center, prospective GORE ® ACUSEAL Vascular Graft compared to historical control.
Patient Population
ESRD patients either currently receiving hemodialysis or expected to require hemodialysis through a prosthetic vascular access graft within 30 days.
Primary Efficacy Endpoint
Cumulative patency at 6 months -Percentage of subjects free from complete loss of access for hemodialysis at the study access site.
Primary Safety Endpoint
Freedom from bleeding at 6 months -Percentage of subjects free from both major and minor bleeding events.
Sample Size N = 138
Follow-Up 1 year 
Objective:
We compare CVC sepsis costs for patients implanted with the early cannulation GORE ® ACUSEAL Vascular Graft to patients with non-early cannulation AVGs (ecAVGs).
Methods:
An economic cost model was estimated using the GORE ® ACUSEAL Vascular Graft clinical study, 4 clinical literature for the non-ecAVG, and publicly available cost sources.
The GORE ® ACUSEAL Vascular Graft clinical study was a prospective, multi-center, single-arm study to establish the safety and efficacy of the GORE ® ACUSEAL Vascular Graft for use in hemodialysis access (Table 1) . 
Economic value of preventing central venous catheter sepsis infections with early cannulation arteriovenous grafts (ecAVGs) compared to non-ecAVGs

Conclusion:
It is estimated the GORE ® ACUSEAL Vascular Graft reduces the overall incidence of CVC sepsis and related costs compared to non-ecAVGs due to fewer CVC-dependent days.
As clinicians become more accustomed to cannulating the GORE ® ACUSEAL Vascular Graft within 24 hours, the cost savings could potentially be higher than what is currently estimated.
Forearm Loop Arteriovenous Graft for Hemodialysis Access
Cannulation of an Arteriovenous Graft
Results:
Assuming 100 patients in each group, the GORE ® ACUSEAL Vascular Graft group was estimated to have 9.9 CVC sepsis episodes compared to 21.6 in the non-ecAVG group, with estimated total sepsis hospitalization costs of $268,171 versus $585,101, respectively, due to the extended time with the CVC (Table 2) .
On average, the GORE ® ACUSEAL Vascular Graft was estimated to reduce the number of CVC sepsis episodes by 11.7 since it reduces the number of catheter-dependent days by 18.5 compared to a non-ecAVG. 
